Why the study?
Does bezafibrate attenuate pressure overload-induced cardiac hypertrophy and fibrosis in mice and cardiomyocytes?
Population
Mice subjected to aortic banding (AB) surgery, and neonatal rat ventricular cardiomyocytes (NRVMs)
Comparison
Bezafibrate 100 mg/kg orally for 7 weeks… vs Control/vehicle (implied)
Design
Preclinical
Follow-up
7 weeks
Authors
Loading...
Should not yet change practice; hypothesis-generating for PPAR-α agonism in pressure-overload remodeling.
Does bezafibrate attenuate pressure overload-induced cardiac hypertrophy and fibrosis in mice and cardiomyocytes?
Bezafibrate, a PPAR-α agonist, protects against pressure overload-induced cardiac hypertrophy and fibrosis in preclinical models.
Xu et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: